Eli Lilly (LLY) will pay Australian biopharma CSL (CSLLY) $100M for a license to explore additional indications for the anti-IL-6 monoclonal antibody clazakizumab.
The biologic is currently in phase 3 development to prevent cardiovascular events in individuals with end-stage kidney disease. CSL retains the rights for that indication.
Terms call for CSL to be eligible for milestone payments and royalties on global net sales for clazakizumab indications that Lilly gains approval for.
CSL noted that by inhibiting IL-6 from binding with its receptor, clazakizumab could treat immuno-inflammatory conditions.
